Clinical trial · Observational
High-dose Cytarabine and Survival in AML
Role of Consolidation With High-dose Cytarabine in Overall Survival of Adults With Acute Myeloid Leukemia
NCT01034839CI-TRIAL-00002911completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In adults with acute myeloid leukemia, especially those \< 60 years of age, high-dose cytarabine consolidation therapy has been shown to influence survival, but the appropriate dose has not been defined.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- acute myeloid leukemia, adults
- description
- Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 92 Years
Show eligibility criteria text
Inclusion Criteria: * clinical diagnosis of acute myeloid leukemia * age 18 years or above * must have been treated with potentially curative therapy Exclusion Criteria: * children or age less than 18 years * palliative therapy
References
Publications (0)
Data not yet available
No reference posted for this study.